Literature DB >> 15661634

Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.

Christian A Heidbreder1, Jim J Hagan.   

Abstract

Pharmacological agents have shown limited efficacy and consistency in the treatment of drug addiction. Hence, the development of new medications with improved long-term efficacy and reduced side effects should be given a high priority given the costs to society associated with drug abuse and drug-related pathologies. Neurochemical systems can be significantly altered by repeated exposure to drugs of abuse. These long-term molecular and neurochemical changes might, in turn, explain the core features of addiction--the compulsive seeking and taking of the drug--as well as the risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661634     DOI: 10.1016/j.coph.2004.08.013

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  20 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

2.  Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior.

Authors:  Alexander Kuzmin; Elisabet Jerlhag; Sture Liljequist; Jörgen Engel
Journal:  Psychopharmacology (Berl)       Date:  2008-11-06       Impact factor: 4.530

3.  The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors.

Authors:  Udi E Ghitza; Sarah M Gray; David H Epstein; Kenner C Rice; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2005-12-07       Impact factor: 7.853

4.  Activation of group II metabotropic glutamate receptors inhibits the discriminative stimulus effects of alcohol via selective activity within the amygdala.

Authors:  Reginald Cannady; Julie J M Grondin; Kristen R Fisher; Clyde W Hodge; Joyce Besheer
Journal:  Neuropsychopharmacology       Date:  2011-07-06       Impact factor: 7.853

5.  Preclinical assessment of CNS drug action using eye movements in mice.

Authors:  Hugh Cahill; Amir Rattner; Jeremy Nathans
Journal:  J Clin Invest       Date:  2011-08-08       Impact factor: 14.808

Review 6.  The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?

Authors:  Ji Hoon Yoo; Ian Kitchen; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 7.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

8.  Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Authors:  Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman
Journal:  Mol Neurobiol       Date:  2011-09-24       Impact factor: 5.590

9.  Medication of l-tetrahydropalmatine significantly ameliorates opiate craving and increases the abstinence rate in heroin users: a pilot study.

Authors:  Zheng Yang; Yong-cong Shao; Shi-jiang Li; Jian-lin Qi; Mei-jie Zhang; Wei Hao; Guo-zhang Jin
Journal:  Acta Pharmacol Sin       Date:  2008-07       Impact factor: 6.150

10.  Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Authors:  Yunden Jinsmaa; Ewa D Marczak; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.